Low-dose naproxen increases frequency of adverse health effects and does not reduce progression of presymptomatic Alzheimer disease in cognitively intact persons at risk.
Low scam awareness is associated with an increased risk for Alzheimer disease and mild cognitive impairment among older adults.
Antiepileptic drug (AED) use may increase the risk for pneumonia in patients with Alzheimer disease.
Use of the orally administered β-site amyloid precursor protein-cleaving enzyme 1 inhibitors, verubecestat and atabecestat, does not prevent clinical progression to Alzheimer disease.
Gerontologists, practicing ethicists, policymakers, and health practitioners should consider the structural conditions of long-term care that both foster aggression and constrain prevention efforts, according to this commentary.
After adjusting for the competing risk of death without dementia, smoking is not associated with an increased risk for dementia.
Patients with poor cognitive function have significantly lower levels of Alzheimer disease-related biomarkers in the vitreous humor.
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.
Alzheimer disease and dementia trials discontinued following disappointing results.
Memantine monotherapy was associated with a 7% lower risk for any cardiovascular event compared with both acetylcholinesterase inhibitor monotherapy and combination therapy, according to a new study.